pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLCpulmo-19Research ArticleКЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИCLINICAL GUIDELINESСочетание хронической обструктивной болезни легких и бронхиальной астмы: согласительный документ Испанского общества пульмонологов и торакальных хирурговChronic obstructive pulmonary disease associated with asthma. Consensus document of Spanish Society of Pulmonologists and Thoracic Surgeons (SEPAR)РедакционнаястатьяArticleEditorial201328022013011319Copyright © Редакционная с., 20132013Редакционная с.article E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/19

Сочетание хронической обструктивной болезни легких и бронхиальной астмы: согласительный документ Испанского общества пульмонологов и торакальных хирургов.

Chronic obstructive pulmonary disease associated with asthma. Consensus document of Spanish Society of Pulmonologists and Thoracic Surgeons (SEPAR).

астмахроническая обструктивная болезнь легкихзаболевание органов дыханиядиагностикалечениефенотипasthmachronic obstructive pulmonary diseaserespiratory diseasediagnosistreatmentphenotypeReferencesPeces–Barba G., Barbera J.A., Agusti A. et al. Guia Clinica SEPARALAT de diagnostico y tratamiento de la EPOC. Arch. Bronconeumol. 2008; 44: 271–281.Peces–Barba G., Barbera J.A., Agusti A. et al. Guia Clinica SEPARALAT de diagnostico y tratamiento de la EPOC. Arch. Bronconeumol. 2008; 44: 271–281.GEMA 2009. Guia Espanola para el Manejo del Asma. Madrid: Luzan; 2009.GEMA 2009. Guia Espanola para el Manejo del Asma. Madrid: Luzan; 2009.Gibson P.G., Simpson J.L. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009; 64: 728–735.Gibson P.G., Simpson J.L. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009; 64: 728–735.Tashkin D.P., Celli B., Decramer M. et al. Bronchodilator responsiveness in patients with COPD. Eur. Respir. J. 2008; 31: 742–750.Tashkin D.P., Celli B., Decramer M. et al. Bronchodilator responsiveness in patients with COPD. Eur. Respir. J. 2008; 31: 742–750.Siva R., Green R.H., Brightling C.E. et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur. Respir. J. 2007; 29: 906–913.Siva R., Green R.H., Brightling C.E. et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur. Respir. J. 2007; 29: 906–913.Miravitlles M. Tratamiento individualizado de la EPOC: una propuesta de cambio. Arch. Bronconeumol. 2009; 45 (Suppl. 5): 27–34.Miravitlles M. Tratamiento individualizado de la EPOC: una propuesta de cambio. Arch. Bronconeumol. 2009; 45 (Suppl. 5): 27–34.Miravitlles M., Calle M., Soler–Cataluña J.J. Fenotipos clinicos de la EPOC. Identificacion, definicion e implicacion es paralas guias de tratamiento. Arch. Bronconeumol. 2011, doi:10.1016/j.arbres.2011.10.007.Miravitlles M., Calle M., Soler–Cataluña J.J. Fenotipos clinicos de la EPOC. Identificacion, definicion e implicacion es paralas guias de tratamiento. Arch. Bronconeumol. 2011, doi:10.1016/j.arbres.2011.10.007.Herland K., Akselsen J.P., Skjonsberg O.H., Bjermer L. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir. Med. 2005; 99: 11–19.Herland K., Akselsen J.P., Skjonsberg O.H., Bjermer L. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir. Med. 2005; 99: 11–19.Petty T.L. The history of COPD. Int. J. Chron. Obstruct. Pulm. Dis. 2006; 1: 3–14.Petty T.L. The history of COPD. Int. J. Chron. Obstruct. Pulm. Dis. 2006; 1: 3–14.UNICEF. Visualisation in participatory programmes. A manual for facilitators and trainers involved in participatory group events. Bangladesh; 1993 [accessed 2011]. Available from: http://portals.wi.wur.nl/files/docs/ppme/VIPP_Unicef.pdfUNICEF. Visualisation in participatory programmes. A manual for facilitators and trainers involved in participatory group events. Bangladesh; 1993 [accessed 2011]. Available from: http://portals.wi.wur.nl/files/docs/ppme/VIPP_Unicef.pdfKaner S., Lind L., Toldi C. A facilitator's guide to participatory decision making. USA: John Wiley & Sons / Jossey–Bass; 2007.Kaner S., Lind L., Toldi C. A facilitator's guide to participatory decision making. USA: John Wiley & Sons / Jossey–Bass; 2007.Burrows B., Bloom J.W., Traver G.A., Cline M.G. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N. Engl. J. Med. 1987; 317: 1309–1314.Burrows B., Bloom J.W., Traver G.A., Cline M.G. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N. Engl. J. Med. 1987; 317: 1309–1314.Orie N.G.M., Sluiter H.J., De Vries K. et al. The host factor in bronchitis. In: Orie N.G.M., Sluiter H.J., eds. Bronchitis. Assen, Netherlands: Royal Van Gorcum; 1961. 43–59.Orie N.G.M., Sluiter H.J., De Vries K. et al. The host factor in bronchitis. In: Orie N.G.M., Sluiter H.J., eds. Bronchitis. Assen, Netherlands: Royal Van Gorcum; 1961. 43–59.Tinkelman D.G., Price D.B., Nordyke R.J. et al. Symptom based questionnaire for differentiating COPD and asthma. Respiration 2006; 73: 296–305.Tinkelman D.G., Price D.B., Nordyke R.J. et al. Symptom based questionnaire for differentiating COPD and asthma. Respiration 2006; 73: 296–305.Leigh R., Pizzichini M.M., Morris M.M. et al. Stable COPD: predicting benefit from high–dose inhaled corticosteroid treatment. Eur. Respir. J. 2006; 27: 964–971.Leigh R., Pizzichini M.M., Morris M.M. et al. Stable COPD: predicting benefit from high–dose inhaled corticosteroid treatment. Eur. Respir. J. 2006; 27: 964–971.Williamson P.A., Menzies D., Clearie K.L. et al. Dose–response for inhaled fluticasone on airway and systemic inflammation in COPD. Eur. Respir. J. 2011; 37: 206–209.Williamson P.A., Menzies D., Clearie K.L. et al. Dose–response for inhaled fluticasone on airway and systemic inflammation in COPD. Eur. Respir. J. 2011; 37: 206–209.Welte T., Miravitlles M., Hernandez P. et al. Efficacy and tolerability of budesonide / formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180: 741–750.Welte T., Miravitlles M., Hernandez P. et al. Efficacy and tolerability of budesonide / formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180: 741–750.Van der Valk P., Monninkhof E., van der Palen J. et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am. J. Respir. Crit. Care Med. 2002; 166: 1358–1363.Van der Valk P., Monninkhof E., van der Palen J. et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am. J. Respir. Crit. Care Med. 2002; 166: 1358–1363.Wouters E.F., Postma D.S., Fokkens B. et al., COSMIC (COPD, Seretide: a Multi–Center Intervention, Characterization) Study Group. Withdrawal of fluticasone propionate from combined salmeterol / fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005; 60: 480–487.Wouters E.F., Postma D.S., Fokkens B. et al., COSMIC (COPD, Seretide: a Multi–Center Intervention, Characterization) Study Group. Withdrawal of fluticasone propionate from combined salmeterol / fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005; 60: 480–487.Cosio B.G., Fiorentino F., Scrimini S. EPOC y asma. Arch. Bronconeumol. 2010; 46 (Suppl. 8): 2–7.Cosio B.G., Fiorentino F., Scrimini S. EPOC y asma. Arch. Bronconeumol. 2010; 46 (Suppl. 8): 2–7.Brindicci C., Ito K., Resta O. et al. Exhaled nitric oxide from lung periphery is increased in COPD. Eur. Respir. J. 2005; 26: 52–59.Brindicci C., Ito K., Resta O. et al. Exhaled nitric oxide from lung periphery is increased in COPD. Eur. Respir. J. 2005; 26: 52–59.Rutgers S.R., van der Mark T.W., Coers W. et al. Markers of nitric oxide metabolism in sputum and exhaled air are not increased in chronic obstructive pulmonary disease. Thorax 1999; 54: 566–580.Rutgers S.R., van der Mark T.W., Coers W. et al. Markers of nitric oxide metabolism in sputum and exhaled air are not increased in chronic obstructive pulmonary disease. Thorax 1999; 54: 566–580.Papi A., Romagnoli M., Baraldo S. et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 162: 1773–1777.Papi A., Romagnoli M., Baraldo S. et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 162: 1773–1777.Lehtimaki L., Kankaanranta H., Saarelainen S. et al. Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD. Eur. Respir. J. 2010; 35: 72–78.Lehtimaki L., Kankaanranta H., Saarelainen S. et al. Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD. Eur. Respir. J. 2010; 35: 72–78.Singh S., Amin A.V., Loke Y.K. Long–term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta–analysis. Arch. Intern. Med. 2009; 169: 219–229.Singh S., Amin A.V., Loke Y.K. Long–term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta–analysis. Arch. Intern. Med. 2009; 169: 219–229.Nelson H.S., Weiss S.T., Bleecker E.R. et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15–26.Nelson H.S., Weiss S.T., Bleecker E.R. et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15–26.Barnes P.J. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc. Am. Thorac. Soc. 2005; 2: 334–339.Barnes P.J. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc. Am. Thorac. Soc. 2005; 2: 334–339.Han M.K., Agusti A., Calverley P.M. et al. Chronic obstructive pulmonary disease phenotypes. The future of COPD. Am. J. Respir. Crit. Care Med. 2010; 182: 598–604.Han M.K., Agusti A., Calverley P.M. et al. Chronic obstructive pulmonary disease phenotypes. The future of COPD. Am. J. Respir. Crit. Care Med. 2010; 182: 598–604.Hardin M., Silverman E.K., Barr R.G. et al. The clinical features of the overlap between COPD and asthma. Respir. Res. 2011; 12: 127; doi: 10.1186/1465–9921–12–127.Hardin M., Silverman E.K., Barr R.G. et al. The clinical features of the overlap between COPD and asthma. Respir. Res. 2011; 12: 127; doi: 10.1186/1465–9921–12–127.Hospers J.J., Postma D.S., Rijcken B. et al. Histamine airway hyper–responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000; 356: 1313–1317.Hospers J.J., Postma D.S., Rijcken B. et al. Histamine airway hyper–responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000; 356: 1313–1317.Vestbo J., Edwards L.D., Scanlon P.D. et al. Changes in forced expiratory volume in 1 second overtime in COPD. N. Engl. J. Med. 2011; 365: 1184–1192.Vestbo J., Edwards L.D., Scanlon P.D. et al. Changes in forced expiratory volume in 1 second overtime in COPD. N. Engl. J. Med. 2011; 365: 1184–1192.Grupo de trabajo de GESEPOC. Hacia un nuevo enfoqueen el tratamiento de la EPOC. Guia Espahola de la EPOC (GESEPOC). Arch. Bronconeumol. 2011; 47: 379–381.Grupo de trabajo de GESEPOC. Hacia un nuevo enfoqueen el tratamiento de la EPOC. Guia Espahola de la EPOC (GESEPOC). Arch. Bronconeumol. 2011; 47: 379–381.Nadeem N.J., Taylor S.J., Eldridge S.M. Withdrawal of inhaled corticosteroids in individuals with COPD – a systematic review and comment on trial methodology. Respir. Res. 2011; 12: 107.Nadeem N.J., Taylor S.J., Eldridge S.M. Withdrawal of inhaled corticosteroids in individuals with COPD – a systematic review and comment on trial methodology. Respir. Res. 2011; 12: 107.

The authors declare that there are no conflicts of interest present.